Bucillamine - Revive Therapeutics

Drug Profile

Bucillamine - Revive Therapeutics

Alternative Names: REV-002; REV-004; REV-005

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Revive Therapeutics
  • Class Cysteines; Disease-modifying antirheumatics; Nonsteroidal anti-inflammatories; Small molecules; Sulfhydryl compounds; Sulfur amino acids
  • Mechanism of Action Chelating agents; Immunomodulators; Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystinuria
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cystinuria; Gout
  • Phase I Hepatolenticular degeneration

Most Recent Events

  • 12 Oct 2017 Chemical structure information added
  • 01 Mar 2017 Phase-II clinical trials in Cystinuria in USA (PO) (NCT02942420)
  • 06 Jul 2016 The US FDA accepts IND application for bucillamine in Cystinuria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top